Axon Enterprise, Inc. (NASDAQ:AXON – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the thirteen brokerages that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and twelve have given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $427.83.
Several brokerages recently commented on AXON. Craig Hallum upped their price target on shares of Axon Enterprise from $370.00 to $376.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Northland Securities upped their price target on Axon Enterprise from $365.00 to $550.00 and gave the stock an “outperform” rating in a report on Monday, November 11th. Robert W. Baird raised their target price on Axon Enterprise from $440.00 to $460.00 and gave the company an “outperform” rating in a research note on Monday, November 4th. The Goldman Sachs Group lifted their price target on shares of Axon Enterprise from $385.00 to $441.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. Finally, Barclays increased their price target on shares of Axon Enterprise from $381.00 to $387.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th.
Check Out Our Latest Research Report on Axon Enterprise
Insider Activity
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of AXON. Blue Trust Inc. boosted its position in shares of Axon Enterprise by 987.5% during the second quarter. Blue Trust Inc. now owns 87 shares of the biotechnology company’s stock worth $27,000 after buying an additional 79 shares during the period. Quent Capital LLC raised its stake in Axon Enterprise by 1,875.0% during the 3rd quarter. Quent Capital LLC now owns 79 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 75 shares in the last quarter. Prestige Wealth Management Group LLC boosted its position in Axon Enterprise by 115.8% during the 3rd quarter. Prestige Wealth Management Group LLC now owns 82 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 44 shares during the period. Brooklyn Investment Group bought a new position in shares of Axon Enterprise in the third quarter worth $41,000. Finally, Asset Dedication LLC acquired a new position in shares of Axon Enterprise during the second quarter valued at $47,000. Institutional investors own 79.08% of the company’s stock.
Axon Enterprise Price Performance
Shares of NASDAQ:AXON opened at $599.35 on Monday. Axon Enterprise has a 52 week low of $220.78 and a 52 week high of $624.84. The business has a fifty day simple moving average of $438.79 and a 200-day simple moving average of $357.90. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32. The company has a market cap of $45.70 billion, a P/E ratio of 154.87, a P/E/G ratio of 15.05 and a beta of 0.94.
About Axon Enterprise
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Featured Stories
- Five stocks we like better than Axon Enterprise
- With Risk Tolerance, One Size Does Not Fit All
- Warren Buffett, Cathie Wood Own Nu Holdings, Should You?
- What Are the U.K. Market Holidays? How to Invest and Trade
- MercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?
- What is the Australian Securities Exchange (ASX)
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.